ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2024
The use of intraluminal PRESERFLO stenting in avoiding early postoperative hypotony.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of PreserFlo MicroShunt versus trabeculectomy in glaucoma patients: a systematic review, meta-analysis, and meta-regression of clinical outcomes and key covariates.BMC ophthalmology · 2026Pooled it
- Factors Associated with Favorable One-Year Outcomes After PreserFlo MicroShunt Implantation: Insights from Anterior Segment Optical Coherence Tomography.Advances in therapy · 2026Article
- Comparison of one-year postoperative outcomes between PreserFlo MicroShunt and trabeculectomy in Japanese patients with open angle glaucoma: a retrospective cohort study using propensity score matching.Japanese journal of ophthalmology · 2026Observational
- Incidence, risk factors, and outcomes of numerical hypotony and choroidal effusion following PRESERFLO MicroShunt implantation.Acta ophthalmologica · 2026Article
- A-stream glaucoma shunt versus trabeculectomy: 1-year results on efficacy and safety.Scientific reports · 2026Article
- Efficacy of Intraoperative 9-0 Nylon Thread Insertion for Preventing Hypotony-Related Complications Following PreserFlo MicroShunt Implantation in Japanese Patients: A Comparative Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Early Clinical Experience with the Novel A-Stream Glaucoma Shunt Combined with Mid-Posterior Tenon's Capsule Advancement Flap.Journal of clinical medicine · 2025Article
- 3-year real-world outcomes of standalone PreserFlo MicroShunt implantation - effectiveness and safety profile.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Intraluminal 10-0 Nylon Stenting in PRESERFLO™ MicroShunt Surgery for Pseudoexfoliation Glaucoma.Journal of clinical medicine · 2025Article
- Prolene suture stenting: a novel approach to mitigate postoperative hypotony in PRESERFLO MicroShunt surgery.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- In vitro flow properties of Preserflo Michroshunt with an intraluminal stent.Eye (London, England) · 2025Article
- Response to letter to the editor regarding "Prolene suture stenting: a novel approach to mitigate postoperative hypotony in PRESERFLO MicroShunt surgery".Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Short-term efficacy and safety of A-stream glaucoma shunt: a 6-month study.Eye (London, England) · 2025Article
- Risk factors and protective strategies for hypotony following preserflo microshunt implantation.Scientific reports · 2025Article
- One-Year Comparison of Efficacy and Safety of PreserFlo MicroShunt with Mitomycin C Applied by Sub-Tenon Injection Versus Sponge.Ophthalmology and therapy · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePostoperative hypotony following PRESERFLO MicroShunt (PMS) implantation is a frequent cause of complications such as choroidal detachment and hypotony maculopathy. This study aims at evaluating the impact of intraluminal stenting of the PMS during the early postoperative period.
methodsWe retrospectively analyzed the data of 97 patients who underwent PMS implantation with intraoperative placement of a Nylon 10-0 suture as intraluminal stent (PStent) and compared the outcomes to those of an existing database of the traditional MicroShunt implantation technique (PTrad, n = 120). The primary outcome measure was the intraocular pressure (IOP) at one week postoperatively. As a secondary outcome measure, adverse hypotony, defined as an IOP ≤ 5 mmHg with significant choroidal effusion and/or anterior chamber shallowing or the presence of macular folds was also assessed. Additionally, the time to stent removal and the IOP one week after stent removal were reported.
resultsPreoperative median IOP was 25.0 (20.5-30.3) mmHg in PStent and 25.0 (19.3-32.0) mmHg in PTrad (p = 0.62). One week after surgery, the median IOP dropped to 10.0 (8.0-13.0) mmHg in PStent and 7.0 (5.0-9.0) in PTrad (p < 0.01). At one month, the IOP was 12.0 (10.0-14.0) mmHg in PStent and 10.0 (8.0-11.0) mmHg in PTrad (p < 0.01). After 3 months, both groups showed similar median IOP levels of 11.0 (8.0-13.5) mmHg and 10.0 (9.75-13.0) mmHg in PStent and PTrad, respectively (p = 0.66). The presence of adverse hypotony was significantly lower in PStent compared to PTrad (6.2% vs 15.8%, p < 0.05). In PStent the stent was removed after 30.0 (21.0-42.5) days. One week after stent removal the mean IOP drop was 6.1 ± 0.5 mmHg (p < 0.01).
conclusionIn the early follow-up period, intraluminal stenting of the PMS appears to be safe and effective in controlling the IOP while reducing early postoperative hypotony. Surgical success is not compromised by stent placement. Based on our data, it is recommended to remove the suture two to six weeks after surgery for most patients with uncomplicated postoperative clinical findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.